If you got your semaglutide or tirzepatide from a compounding pharmacy — through a telehealth platform, a med spa, or a local compounder — 2026 is the year that path likely closed.
The regulatory landscape has been shifting since late 2024, when the FDA removed both semaglutide and tirzepatide from the official drug shortage list. Under federal law (Section 503A of the Federal Food, Drug, and Cosmetic Act), compounding pharmacies may produce versions of FDA-approved drugs only when those drugs are in declared shortage. When the shortage ends, the legal basis for compounding the active ingredients ends with it.
Through 2025, enforcement was uneven. Some compounders continued operating in a gray zone, citing supply gaps and patient-specific medical necessity exceptions. Eli Lilly and Novo Nordisk filed dozens of lawsuits. State boards of pharmacy issued warnings.
In Q1 2026, the FDA moved decisively. Multiple enforcement actions against the largest telehealth GLP-1 platforms were announced in March and April. State pharmacy boards in Texas, Florida, and California — states with the highest density of compounding activity — issued mandatory cease-production orders for branded compound formulations of semaglutide and tirzepatide. The Federation of State Medical Boards published updated guidance in May classifying continued compounded GLP-1 prescribing as outside the standard of care absent documented patient-specific medical necessity.
The result: hundreds of thousands of women who built their GLP-1 protocols around compounded access are facing involuntary discontinuation.
What this looks like in practice
Three patterns are emerging:
Sudden cancellation. A woman receives an email from her telehealth provider stating that her next shipment has been suspended pending regulatory review, or that the provider is exiting compounded GLP-1 services entirely. Lead time: often zero, sometimes 2-4 weeks of remaining supply.
Bait-and-switch to branded. The provider offers to transition the patient to FDA-approved Wegovy/Zepbound at retail pricing — typically $1,300-1,800/month out-of-pocket if uncovered by insurance, versus the $200-400/month many compounded patients had been paying.
Quiet supply degradation. A compounder continues to operate but with longer fulfillment times, sporadic stock outs, and inconsistent dose availability. Patients end up effectively self-tapering through forced interruptions.
In all three scenarios, the woman experiences what the medical literature calls an “unstructured discontinuation” — an exit driven by external circumstances rather than a deliberate clinical plan. The data on unstructured discontinuation is consistent: it produces worse regain outcomes than planned tapers, almost entirely because of the absence of pre-installed behavioral structure.
Hundreds of thousands of women who built their GLP-1 protocols around compounded access are facing involuntary discontinuation.
What the literature says about forced exit
The 2026 European GLP-1 Discontinuation Observatory study (published in Diabetes Care, March 2026) followed 1,247 patients across the EU who experienced forced discontinuation due to supply or insurance interruption, and compared their outcomes against a matched cohort of planned discontinuations.
The forced-discontinuation group:
- ✓ Regained an average of 68% of their lost weight at 12 months — vs. 52% in the planned-discontinuation group
- ✓ Reported substantially higher rates of binge-eating-pattern behavior in the first 3 months post-discontinuation
- ✓ Showed higher rates of psychological distress and grief-related symptoms at 6-month follow-up
- ✓ Were less likely to have a structured maintenance protocol in place when the medication ended
The last bullet is the actionable one. The other differences are largely downstream of it.
What to do if you’re in the gap
If you’re reading this and you’re either currently on compounded GLP-1 with uncertain supply, or you’ve just experienced an involuntary discontinuation:
One: don’t panic-stockpile. Buying 6 months of compounded supply from a sketchy source to extend your protocol is the worst possible move. The 2026 enforcement actions specifically targeted compounders with quality-control failures — sub-potent and contaminated batches are documented. The risk-adjusted value of compounded supply has dropped sharply.
Two: have the branded conversation with your prescriber. For some women, branded Wegovy or Zepbound is financially feasible, especially with manufacturer copay savings programs (which have expanded substantially in 2026 as the brands fight for market share). For others, it’s not. Get the actual number before you decide it’s impossible.
Three: consider the maintenance-dose option discussed elsewhere in this journal. If the cost gap between continued branded therapeutic-dose treatment and full discontinuation is large, an ultra-low maintenance dose may bridge it. See our piece on the maintenance dose question for details. Your prescriber may not have offered this; it’s an emerging option.
Four: install the maintenance protocol immediately. The single most actionable difference between the forced-discontinuation group and the planned-discontinuation group in the European observatory study was whether a structured behavioral protocol was already running when the medication ended. If you’re facing imminent forced discontinuation, getting that protocol installed in the next 4-8 weeks is the highest-leverage move available to you.
This is the specific window WeWontRegain’s Stabilize Phase is designed for. Members who join during a forced-discontinuation event consistently outperform their matched peers in the literature, by substantial margins.
Forced discontinuation is the hardest exit, and it’s also the most fixable with the right protocol installed in the first 60 days. We accept members at any phase of GLP-1 use or discontinuation, including those caught in supply gaps. Schedule a free consult →
The grief no one talks about
A note on the psychological dimension, which the clinical literature is starting to take seriously and which the wellness industry continues to mostly miss.
For many women, the GLP-1 wasn’t just a medication. It was the first thing in their adult life that quieted the food noise discussed in our piece on the neural signature. The first relationship with food that didn’t involve constant cognitive load. The first time they felt at peace with eating.
Being forced off of that — not because of side effects, not because the work was done, but because of a regulatory cleanup — produces something that looks a lot like grief. It’s grief for the version of yourself the drug let you become. It’s grief for the constancy of mind you didn’t know was possible until you experienced it. It’s grief for the trust you placed in a system that turned out to be more contingent than you knew.
This grief is real. It’s also processable. The maintenance protocol that addresses your hunger system and your training and your sleep also has to address your emotional relationship with the medication that’s now ending. The 1:1 work is where this happens.
If forced discontinuation is your story, you’re not alone in it and you’re not at the end of your options. The protocol is the path forward. Talk to us free for 15 minutes →
Sources & methodology note
Primary references: FDA enforcement actions, March-May 2026 (publicly available via FDA Office of Compliance press announcements); Federation of State Medical Boards guidance, May 2026; European GLP-1 Discontinuation Observatory cohort study (Diabetes Care, March 2026). Regulatory landscape is fast-moving; current status should be confirmed with your prescriber. Nothing in this piece constitutes medical or legal advice.